These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 25394645)

  • 21. Paclitaxel is necessary for improved survival in epithelial ovarian cancers with homologous recombination gene mutations.
    Jean S; Li J; Katsaros D; Wubbenhorst B; Maxwell KN; Fishbein L; McLane MW; Benedetto C; Canuto EM; Mitra N; Zhang L; Nathanson KL; Tanyi JL
    Oncotarget; 2016 Jul; 7(30):48577-48585. PubMed ID: 27191893
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Exon 4 deletion variant of epidermal growth factor receptor enhances invasiveness and cisplatin resistance in epithelial ovarian cancer.
    Zhang P; Zhang P; Zhou M; Jiang H; Zhang H; Shi B; Pan X; Gao H; Sun H; Li Z
    Carcinogenesis; 2013 Nov; 34(11):2639-46. PubMed ID: 23764753
    [TBL] [Abstract][Full Text] [Related]  

  • 23. IL-6R/STAT3/miR-204 feedback loop contributes to cisplatin resistance of epithelial ovarian cancer cells.
    Zhu X; Shen H; Yin X; Long L; Chen X; Feng F; Liu Y; Zhao P; Xu Y; Li M; Xu W; Li Y
    Oncotarget; 2017 Jun; 8(24):39154-39166. PubMed ID: 28388577
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line.
    Lee S; Choi EJ; Jin C; Kim DH
    Gynecol Oncol; 2005 Apr; 97(1):26-34. PubMed ID: 15790433
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Highly expressed NRSN2 is related to malignant phenotype in ovarian cancer.
    Tang W; Ren A; Xiao H; Sun H; Li B
    Biomed Pharmacother; 2017 Jan; 85():248-255. PubMed ID: 27908706
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Knockdown of MACC1 expression increases cisplatin sensitivity in cisplatin-resistant epithelial ovarian cancer cells.
    Zhang R; Shi H; Ren F; Li X; Zhang M; Feng W; Jia Y
    Oncol Rep; 2016 Apr; 35(4):2466-72. PubMed ID: 26794135
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Short-term single treatment of chemotherapy results in the enrichment of ovarian cancer stem cell-like cells leading to an increased tumor burden.
    Abubaker K; Latifi A; Luwor R; Nazaretian S; Zhu H; Quinn MA; Thompson EW; Findlay JK; Ahmed N
    Mol Cancer; 2013 Mar; 12():24. PubMed ID: 23537295
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tribbles 2 mediates cisplatin sensitivity and DNA damage response in epithelial ovarian cancer.
    Kritsch D; Hoffmann F; Steinbach D; Jansen L; Mary Photini S; Gajda M; Mosig AS; Sonnemann J; Peters S; Melnikova M; Thomale J; Dürst M; Runnebaum IB; Häfner N
    Int J Cancer; 2017 Oct; 141(8):1600-1614. PubMed ID: 28670762
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Cisplatin resistant effects of dihydrofolate reductase gene expression up-regulation in epithelial ovarian cancer].
    Li Z; Wang Q; Zhang W; Yang Z; Li L
    Zhonghua Fu Chan Ke Za Zhi; 2015 Nov; 50(11):854-60. PubMed ID: 26887775
    [TBL] [Abstract][Full Text] [Related]  

  • 30. COL11A1 confers chemoresistance on ovarian cancer cells through the activation of Akt/c/EBPβ pathway and PDK1 stabilization.
    Wu YH; Chang TH; Huang YF; Chen CC; Chou CY
    Oncotarget; 2015 Sep; 6(27):23748-63. PubMed ID: 26087191
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of p53 induces invasion of serous borderline ovarian tumor cells by accentuating PI3K/Akt-mediated suppression of E-cadherin.
    Cheng JC; Auersperg N; Leung PC
    Oncogene; 2011 Mar; 30(9):1020-31. PubMed ID: 20972462
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association of expression of XIAP-associated factor 1 (XAF1) with clinicopathologic factors, overall survival, microvessel density and cisplatin-resistance in ovarian cancer.
    Wang Y; Mao H; Hao Q; Wang Y; Yang Y; Shen L; Huang S; Liu P
    Regul Pept; 2012 Oct; 178(1-3):36-42. PubMed ID: 22759793
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting FOXM1 Improves Cytotoxicity of Paclitaxel and Cisplatinum in Platinum-Resistant Ovarian Cancer.
    Westhoff GL; Chen Y; Teng NNH
    Int J Gynecol Cancer; 2017 Oct; 27(8):1602-1609. PubMed ID: 28692634
    [TBL] [Abstract][Full Text] [Related]  

  • 34. DYRK2 regulates epithelial-mesenchymal-transition and chemosensitivity through Snail degradation in ovarian serous adenocarcinoma.
    Yamaguchi N; Mimoto R; Yanaihara N; Imawari Y; Hirooka S; Okamoto A; Yoshida K
    Tumour Biol; 2015 Aug; 36(8):5913-23. PubMed ID: 25712377
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Epithelial-mesenchymal status renders differential responses to cisplatin in ovarian cancer.
    Miow QH; Tan TZ; Ye J; Lau JA; Yokomizo T; Thiery JP; Mori S
    Oncogene; 2015 Apr; 34(15):1899-907. PubMed ID: 24858042
    [TBL] [Abstract][Full Text] [Related]  

  • 36. miR-215 functions as a tumor suppressor in epithelial ovarian cancer through regulation of the X-chromosome-linked inhibitor of apoptosis.
    Ge G; Zhang W; Niu L; Yan Y; Ren Y; Zou Y
    Oncol Rep; 2016 Mar; 35(3):1816-22. PubMed ID: 26676658
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of human epididymis protein 4 in chemoresistance and prognosis of epithelial ovarian cancer.
    Lee S; Choi S; Lee Y; Chung D; Hong S; Park N
    J Obstet Gynaecol Res; 2017 Jan; 43(1):220-227. PubMed ID: 27862665
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Malignant ascites enhances migratory and invasive properties of ovarian cancer cells with membrane bound IL-6R in vitro.
    Kim S; Gwak H; Kim HS; Kim B; Dhanasekaran DN; Song YS
    Oncotarget; 2016 Dec; 7(50):83148-83159. PubMed ID: 27825119
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Establishment of paclitaxel-resistant cell line and the underlying mechanism on drug resistance.
    Zhang J; Zhao J; Zhang W; Liu G; Yin D; Li J; Zhang S; Li H
    Int J Gynecol Cancer; 2012 Nov; 22(9):1450-6. PubMed ID: 23051955
    [TBL] [Abstract][Full Text] [Related]  

  • 40. p53 mutations in epithelial ovarian cancers: possible role in predicting chemoresistance.
    Laframboise S; Chapman W; McLaughlin J; Andrulis IL
    Cancer J; 2000; 6(5):302-8. PubMed ID: 11079169
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.